Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

FHS
May 24, 2024
4:39 pm

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

Obesity prevalence and BMI decrease in the US for the first time in a decade

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.

December 16, 2024

Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy -; a cell-based cancer

June 13, 2024

Inovalon & AWS to Develop AI/ML Solutions for Healthcare

What You Should Know: Amazon Web Services and Inovalon announced a collaboration to develop AI and ML-based solutions for healthcare organizations to improve patient outcomes

October 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.